Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 2019-04-30 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 2023-06-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 2021-01-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/1/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 8/1/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 8/1/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 8.19B | |
| -4.10% | -8.54% | +40.05% | +66.99% | 63.29B | |
| -0.15% | +7.50% | +11.01% | +73.48% | 54.89B | |
| +0.51% | +4.70% | +10.17% | +93.04% | 53.28B | |
| +0.61% | +2.69% | +27.75% | +50.97% | 45.81B | |
| -1.08% | +2.19% | +21.92% | +131.38% | 43.46B | |
| -3.39% | -0.83% | +254.27% | +571.04% | 40.23B | |
| -1.67% | +6.70% | +14.42% | +56.67% | 33.45B | |
| +1.19% | -4.98% | +29.01% | -0.76% | 23.7B | |
| -0.53% | +5.80% | +36.58% | +27.69% | 23.76B | |
| Average | -0.78% | +0.46% | +49.47% | +118.94% | 42.43B | |
| Weighted average by Cap. | -1.08% | +0.59% | +47.59% | +122.51% |
Employees
355
